Skip to main content

Table 1 :

From: Treatment of invasive candidiasis with caspofungin in the intensive care unit

  End of IV study therapy Confirmed relapse at 6–8 weeks post-therapy All-cause mortality at 6–8 weeks post-therapy
ICU patients 59/97 (61%) [51%, 71%] 10/59 (17%) [7%, 27%] 41/97 (42%) [32%, 52%]
CAS 27/40 (68%) [53%, 82%] 5/27 (19%) [4%, 33%] 18/40 (45%) [29%, 61%]
AmB 32/57 (56%) [43%, 69%] 5/32 (16%) [3%, 28%] 23/57 (40%) [28%, 53%]
Non-ICU patients 92/127 (72%) [65%, 80%] 5/92 (5%) [1%, 10%] 30/127 (24%) [16%, 31%]
  1. Data presented as m/n (%) [95% confidence intervals].